Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 75/100

Failure Rate

24.0%

6 terminated/withdrawn out of 25 trials

Success Rate

64.7%

-21.8% vs industry average

Late-Stage Pipeline

12%

3 trials in Phase 3/4

Results Transparency

18%

2 of 11 completed trials have results

Key Signals

4 recruiting2 with results

Enrollment Performance

Analytics

Phase 1

14(56.0%)

Phase 2

8(32.0%)

Phase 3

3(12.0%)

25Total

Phase 1(14)

Phase 2(8)

Phase 3(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (25)

Showing 20 of 25 trials

NCT03970447Phase 2Recruiting

A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma

Role: collaborator

NCT05813327Phase 1Active Not Recruiting

Neoadjuvant ADI-PEG 20 + Ifosfamide + Radiotherapy in Soft Tissue Sarcoma

Role: collaborator

NCT05712694Phase 3Recruiting

Study of ADI-PEG 20 or Placebo Plus Gem and Doc in Previously Treated Subjects With Leiomyosarcoma (ARGSARC)

Role: lead

NCT05616624Phase 1Active Not Recruiting

ADI-PEG 20 in Combination With Gemcitabine and Docetaxel After Progression on Frontline Therapy in Non-small Cell and Small Cell Lung Cancers

Role: collaborator

NCT05001828Phase 1Active Not Recruiting

Study of ADI-PEG 20, Venetoclax and Azacitidine in Acute Myeloid Leukemia

Role: lead

NCT05317819Phase 3Recruiting

Study of ADI-PEG 20 Versus Placebo in Subjects With High Arginine Level and Unresectable Hepatocellular Carcinoma

Role: lead

NCT05842512Phase 2Recruiting

Study of ADI-PEG 20 Versus Placebo in Subjects With NASH

Role: lead

NCT04587830Phase 2Active Not Recruiting

ADI-PEG 20 Plus Radiotherapy and Temozolomide in Subjects With Glioblastoma Multiforme

Role: lead

NCT02709512Phase 2Completed

Ph 2/3 Study in Subjects With MPM to Assess ADI-PEG 20 With Pemetrexed and Cisplatin

Role: lead

NCT01266018Phase 2Terminated

Study of ADI-PEG 20 in Patients With Relapsed Sensitive or Refractory Small Cell Lung Cancer

Role: collaborator

NCT03254732Phase 1Terminated

Study ADI-PEG 20 Plus Pembrolizumab in Advanced Solid Cancers

Role: lead

NCT02102022Phase 1Terminated

Ph 1-2 Study ADI-PEG 20 Plus FOLFOX in Subjects With Advanced GI Malignancies Focusing on Hepatocellular Carcinoma

Role: lead

NCT01910012Phase 2Completed

PH 2 ADI-PEG 20 Acute Myeloid Leukemia

Role: lead

NCT02101580Phase 1Completed

Ph 1B Trial With ADI-PEG 20 Plus Nab-Paclitaxel and Gemcitabine in Subjects With Pancreatic Cancer

Role: lead

NCT02029690Phase 1Terminated

Ph 1 Study in Subjects With Tumors Requiring Arginine to Assess ADI-PEG 20 With Pemetrexed and Cisplatin

Role: lead

NCT02875093Phase 1Terminated

Ph 1 Study of ADI-PEG 20 Plus Low Dose Cytarabine in Older Patients With AML

Role: lead

NCT03498222Phase 1Withdrawn

Study in Patients With Tumours Requiring Arginine to Assess ADI-PEG 20 With Atezolizumab, Pemetrexed and Carboplatin

Role: collaborator

NCT01287585Phase 3Completed

Ph 3 ADI-PEG 20 Versus Placebo in Subjects With Advanced Hepatocellular Carcinoma Who Have Failed Prior Systemic Therapy

Role: lead

NCT01910025Phase 2Completed

PH 2 ADI-PEG 20 Study in Non-Hodgkin's Lymphoma Subjects Who Have Failed Prior Systemic Therapy

Role: lead

NCT01497925Phase 1Completed

Ph 1 Trial of ADI-PEG 20 Plus Docetaxel in Solid Tumors With Emphasis on Prostate Cancer and Non-Small Cell Lung Cancer

Role: lead